التفاصيل البيبلوغرافية
| العنوان: |
305 例局部晚期直肠癌术前化疗对比同步 放化疗联合全直肠系膜切除的疗效. (Chinese) |
| Alternate Title: |
Comparison of preoperative chemotherapy with concurrent chemoradiotherapy combined with TME for 305 patients with locally advanced rectal cancer. (English) |
| المؤلفون: |
穆娅莎·阿布力米提, 刘文扬, 金晶, 李帅, 唐源, 李宁, 任骅, 房辉, 卢宁宁, 唐玉, 陈波, 王淑莲, 宋永文, 刘跃平, 亓姝楠, 李晔雄 |
| المصدر: |
Chinese Journal of Oncology; Oct2021, Vol. 43 Issue 10, p1122-1131, 10p |
| Abstract (English): |
To retrospectively analyze the long-term efficacy and prognostic factors of preoperative chemotherapy ( PCT) or chemoradiotherapy ( PCRT) combined with total mesorectal excision in locally advanced rectal cancer. Methods Clinical pathology data of 305 patients with localized advanced rectal cancer admitted to the Cancer Hospital, Chinese Academy of Medical Sciences from 2006 to 2018 were collected, of whom 246 patients received PCRT ( PCRT group), 59 patients received PCT ( PCT group ). Kaplan-Meier and Log rank test were used for the survival analysis, Cox regression model was used for multivariate analysis, and the prognosis of two groups of patients were compared by the propensity score matching (PSM). Results In the whole group of 305 patients, 20 cases of tumors located in the upper part of the rectum and at the junction of rectum and colon, 96 cases in the middle of the rectum and 189 cases in the lower part of the rectum. PCRT group included 38 cases of cT2-3 phase, 11 cases of cT4a stage, 10 cases of cT4b stage, while the cases in PCT group were 184, 0 and 62 cases, respectively, the difference is statistically significant (P c 0. 05 ). The RO excision rates of PCRT group and PCT group were 100% ( 246/246) and 96.6% (57/59), respectively, and the total pathological remission rates were 13.4% and 3.3%, respectively (Pc0.05). After PSM, the 3-year survival rates of PCRT group and the PCT group were 86.6% and 89.9% (P>0.05), respectively, and the progression-free survival rates were 74.6% and 77.2% (P>0.05), local recurring free survival rates were 100% and 92.3% (P> 0.05), distant metastasis free survival rate were 75.6% and 77.3% (P>0.05). Pre-treatment N-positive, N-degeneration and MRF-positive were all associated with total survival (Pc0.05). Conclusion In the PCRT group, with a higher proportion of patients with stage T4b and lower rectal cancer, the long-term efficacy of PCRT was similar to that of PCT, and higher RO excision rate and pathological complete response rate could be obtained. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
目的 分析局部晚期直肠癌术前化疗或放化疗联合全直肠系膜切除的疗效及预后。方法收集 2006一 2018 年中国医学科学院肿瘤医院收治的局部晚期 305 例直肠癌患者的临床病理 资料, 其中 246 例患者接受术前放化疗 (术前放化疗组), 59 例患者接受术前化疗 (术前化疗组), 生存 分析采用 Kaplan-Meier 法和 Log rank 检验, 多因素分析采用 Cox 回归模型, 采用倾向评分匹配 (PSM) 分析两组患者预后。结果全组 305 例患者, 肿瘤位于直肠上段 20 例, 直肠中段 96 例, 直肠下段 189 例。术前化疗组 cT2~3 期 38 例, cT4a 期11例, cT4b 期10例, 术前放化疗组分别为 184\0 和 62 例, 差异有统计学意义 (P<0.05)。术前放化疗组与术前化疗组患者 R0 切除率分别为 100% ( 246/246）和 96.6% ( 57/59), 病理完全缓解率分别为 13.4％ 和 3.3%, 差异均有统计学意义 (P<0.05)。PSM 后, 术 前放化疗组与术前化疗组患者的 3 年生存率分别为 86.6％ 和 89.9% (P>0.05), 无病生存率分别为 74.6％ 和 77.2% ( P>0.05), 无局部复发生存率分别为 96.2％ 和 90.8% (P>0.05), 无远处转移生存率分 别为 75.6％ 和 77.3% ( P>0.05)。治疗前 N 阳性、是否N降期和直肠系膜筋膜阳性均与总生存有关 (均 P<0.05)。结论在术前放化疗组中, T4b 期和下段直肠癌患者比例更高的情况下, 术前放化疗与 术前化疗远期疗效近似, 术前放化疗可获得更高的 R0 切除率和病理完全缓解率。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |